Business Description
Beam Therapeutics Inc
NAICS : 325411
SIC : 2833
ISIN : US07373V1052
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.1 | |||||
Equity-to-Asset | 0.68 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | -1.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 2.03 | |||||
Beneish M-Score | 0.46 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1598 | |||||
3-Year EBITDA Growth Rate | 9.5 | |||||
3-Year EPS without NRI Growth Rate | 15.7 | |||||
3-Year FCF Growth Rate | 0.4 | |||||
3-Year Book Growth Rate | 41 | |||||
Future 3-5Y EPS without NRI Growth Rate | -35.23 | |||||
Future 3-5Y Total Revenue Growth Rate | -43.35 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 10.2 | |||||
12-1 Month Momentum % | -40 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.81 | |||||
Quick Ratio | 5.81 | |||||
Cash Ratio | 5.69 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.6 | |||||
Shareholder Yield % | -3.21 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -52.31 | |||||
Net Margin % | -40.56 | |||||
FCF Margin % | -44.31 | |||||
ROE % | -16.48 | |||||
ROA % | -10.63 | |||||
ROIC % | -46.19 | |||||
ROC (Joel Greenblatt) % | -78.55 | |||||
ROCE % | -16.11 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 5.36 | |||||
PB Ratio | 2.26 | |||||
Price-to-Tangible-Book | 2.26 | |||||
EV-to-EBIT | -5.88 | |||||
EV-to-Forward-EBIT | -3.65 | |||||
EV-to-EBITDA | -6.66 | |||||
EV-to-Forward-EBITDA | -4.09 | |||||
EV-to-Revenue | 3.08 | |||||
EV-to-Forward-Revenue | 37.41 | |||||
EV-to-FCF | -7.07 | |||||
Price-to-Net-Current-Asset-Value | 3.1 | |||||
Price-to-Net-Cash | 3.21 | |||||
Earnings Yield (Greenblatt) % | -17.01 | |||||
FCF Yield % | -7.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Beam Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | 6,072.196 | ||
EPS (TTM) (MXN) | -31.858 | ||
Beta | 0 | ||
Volatility % | 40 | ||
14-Day RSI | 10.2 | ||
14-Day ATR (MXN) | 0.000013 | ||
20-Day SMA (MXN) | 450 | ||
12-1 Month Momentum % | -40 | ||
52-Week Range (MXN) | 440 - 750 | ||
Shares Outstanding (Mil) | 82.42 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Beam Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Beam Therapeutics Inc Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
Beam Therapeutics Inc Frequently Asked Questions
What is Beam Therapeutics Inc(MEX:BEAM)'s stock price today?
When is next earnings date of Beam Therapeutics Inc(MEX:BEAM)?
Does Beam Therapeutics Inc(MEX:BEAM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |